Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer.
Li Y, Yang G, Zhang J, Tang P, Yang C, Wang G, Chen J, Liu J, Zhang L, Ouyang L.
We herein report the identification, structural optimization, and structure-activity relationship of thieno[2,3-<i>d</i>]pyrimidine derivatives as a novel kind of selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors. <i>N</i>-(4-Chloro-3-(trifluoromethyl)phenyl)-4-(6-(4-(4-methylpiperazin-1-yl)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxamide (<b>38k</b>) was the most potent VEGFR3 inhibitor (IC<sub>50</sub> = 110.4 nM) among developed compounds. Compared with VEGFR1 and VEGFR2, VEGFR3 was approximately 100 times more selective. Here, compound <b>38k</b> significantly inhibited proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway. Additionally, <b>38k</b> induced cell apoptosis and a prolonged G1/S-phase in MDA-MB-231 and MDA-MB-436 cells. It also presented acceptable pharmacokinetic characteristics in Sprague-Dawley (SD) rats with an oral bioavailability of 30.9%. In the xenograft model <i>in vivo</i>, <b>38k</b> effectively inhibited breast cancer growth by suppressing the VEGFR3 signaling pathway. <b>38k</b> pronouncedly resisted the formation of pulmonary metastatic nodules in mice. Collectively, <b>38k</b> may be a promising therapeutic agent of metastatic breast cancer.